Comparative Pharmacology
Head-to-head clinical analysis: ADENOCARD versus PRONESTYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOCARD versus PRONESTYL.
ADENOCARD vs PRONESTYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is an endogenous purine nucleoside that acts on A1 and A2 adenosine receptors. It slows conduction through the AV node, interrupts reentry pathways, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT).
Class IA antiarrhythmic; blocks sodium channels, decreases phase 0 upstroke velocity, prolongs action potential duration, and increases effective refractory period.
6 mg IV bolus over 1-2 seconds, followed by 20 mL saline flush; if no conversion to sinus rhythm within 1-2 minutes, give 12 mg IV bolus; may repeat 12 mg once more if needed.
For life-threatening ventricular arrhythmias: loading dose of 100 mg IV over 5 minutes, repeated every 5 minutes as needed up to a total of 1 g. Maintenance: continuous IV infusion of 1-4 mg/min. Oral: 50 mg/kg/day in divided doses every 3-6 hours.
None Documented
None Documented
Terminal half-life is less than 10 seconds; clinically, the effect is very transient due to rapid cellular uptake and metabolism.
3-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment. Clinical context: Requires dosing every 3-4 hours to maintain therapeutic levels; sustained-release formulations allow Q6-8h dosing.
Primarily renal excretion of metabolites; adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with less than 1% excreted unchanged in urine.
Renal excretion accounts for approximately 50-60% of procainamide elimination as unchanged drug, with an additional 10-30% as the active metabolite N-acetylprocainamide (NAPA). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic